Phase III SAFFRON Trial Shows ORPATHYS® Plus TAGRISSO® Improves Outcomes in MET-Driven EGFR-Mutated Lung Cancer

HUTCHMED announced positive results from the global Phase III SAFFRON trial, demonstrating that ORPATHYS® combined with TAGRISSO® significantly reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer patients who had progressed on prior TAGRISSO®. The combination extended median overall survival by nearly five months. These findings were simultaneously published in The New England Journal of Medicine and presented at ESMO Congress 2026.